ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Core Viewpoint - Rosen Law Firm is reminding purchasers of Aldeyra Therapeutics, Inc. securities about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from November 3, 2023, to March 16, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aldeyra securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is May 29, 2026, which is crucial for those wishing to represent other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements recovered for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Aldeyra made false and misleading statements regarding the clinical trials of its drug candidate reproxalap, claiming that the results were inconsistent and rendered any positive findings unreliable [5]. - As a result of these misleading statements, investors suffered damages when the true details became known [5].